Background/Aims: Natriuretic peptides have been reported to be a valuable biomarker for predicting cardiac events and mortality for haemodialysis patients. However, there has been a debate as to whether these biomarkers can be used to assess volume overload and help determine dry weight. Methods: We measured the N-terminal probrain natriuretic peptide (NTproBNP) in 366 stable haemodialysis outpatients with a corresponding pre- and post-dialysis multifrequency bioimpedance assessment of extracellular water (ECW)/total body water (TBW). Results: Median age was 61 years (46–73); 58.5% were male, 28.5% diabetic, and 37.7% Caucasoid; 71.1% had a history of hypertension, 8.4% of myocardial infarction, and 9.3% of coronary artery bypass surgery; dialysis vintage was 54 months (22–85.5), and urea reduction ratio was 73.4 ± 7.6%. Median post-dialysis NTproBNP was 179 pmol/l (68–535), pre-dialysis ECW/TBW was 0.393 ± 0.014, and post-dialysis ECW/TBW was 0.385 ± 0.015. On multivariate analysis log NTproBNP was associated with post-dialysis ECW/TBW (β 9.09, 95% CI 3.22–14.95, p = 0.003), mean arterial pressure (β 0.0087, 95% CI –0.0045 to –0.013, p = 0.000), and ultrafiltration rate (ml/kg· h; β 0.038, 95% CI 0.01–0.06, p = 0.001). Conclusion: In this study postdialysis NTproBNP values were correlated with direct assessments of volume status in haemodialysis patients, i.e. by ECW/TBW, or indirect measures of volume overload, i.e. ultrafiltration rate and post-dialysis mean arterial blood pressure. This suggests that serial NTproBNP values may aid clinical assessments of volume status in dialysis patients.

Keywords:
NTproBNP, Bioimpedance, Extracellular fluid volume, Haemodialysis
1.
Foley RN, Parfrey PS: Cardiovascular disease and mortality in ESRD. J Nephrol 1998;11:239–245.
2.
Davenport A: How best to improve survival in hemodialysis patients: solute clearance or volume control? Kidney Int 2011;80:1018–1020.
3.
FHN Trial Group, Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS: In-center haemodialysis six times per week versus three times per week. N Engl J Med 2010;363:2287–2300.
4.
Sheen V, Bhalla V, Tulua-Tata A, Bhalla MA, Weiss D, Chiu A, Abdeen O, Mullaney S, Maisel A: The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J 2007;153:244.e1–e5.
5.
Palmer SC, Yandle TG, Nicholls MG, Frampton CM, Richards AM: Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma. Eur J Heart Fail 2009;11:832–839.
6.
Papakrivopoulou E, Booth J, Pinney J, Davenport A: Comparison of volume status in asymptomatic haemodialysis and peritoneal dialysis outpatients. Nephron Extra 2012;2:48–54.
7.
Paniagua R, Ventura MD, Avila-Diaz M, Hinojosa-Heredia H, Mendez-Duran A, Cueto-Manzano A, Cisneros A, Ramos A, Mandonia-Juseino C, Belio-Caro F, Garcia-Contreras F, Trinidad-Ramos P, Vazquez R, Ilabaca B, Alcantara G, Amato D: NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant 2009;25:551–557.
8.
David S, Kümpers P, Seidler V, Biertz F, Haller H, Fliser D: Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis Nephrol Dial Transplant 2008;23:1370–1377.
9.
Choi SY, Lee JE, Jang EH, Kim MO, Baek H, Ki CS, Park SW, Kim DJ, Huh WS, Oh HY, Kim YG: Association between changes in N-terminal pro-brain natriuretic peptide levels and changes in left ventricular mass index in stable haemodialysis patients. Nephron Clin Pract 2008;110:c93–c100.
10.
Davenport A, Willicombe MK: Comparison of fluid status in patients treated by different modalities of peritoneal dialysis using multi-frequency bio-impedance. Int J Artif Organs 2009;32:779–786.
11.
Jacobs LH, van der Kerkhof JJ, Mingels AM, Passos VL, Kleijnen VW, Mazairac AH, van der Sande FM, Wodzig WK, Konings VW, Leunissen KM, van Dieijen-Visser MP, Kooman JP: Inflammation overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study. Nephrol Dial Transplant 2009;25:243–248.
12.
Chazot C, Jean G, Vo-Van C, Collonge C, Terrat JC, Vanel T, Lorriaux C, Hurot JM, Charra B: The plasma level of brain natriuretic peptide is increased in malnourished haemodialysis patients. Blood Purif 2009;28:187–192.
13.
Vernon K, Peasegood J, Riddell A, Davenport A: Dialyzers designed to increase internal filtration do not result in significantly increased platelet activation and thrombin generation. Nephron Clin Pract 2011;117:c403–c408.
14.
Davenport A: Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments. Nephrology (Carlton) 2009;14:455–461.
15.
Bedogni G, Malavolti M, Severi S, Poli M, Mussi C, Fantuzzi AL, Battistini N: Accuracy of an eight-point tactile-electrode impedance method in the assessment of total body water. Eur J Clin Nutr 2002;56:1143–1148.
16.
Fürstenberg A, Davenport A: Comparison of multifrequency bioelectrical impedance analysis and dual-energy X-ray absorptiometry assessments in outpatient haemodialysis patients. Am J Kidney Dis 2011;57:123–129.
17.
Chazot C, Vo-Van C, Zaoui E, Vanel T, Hurot JM, Lorriaux C, Mayor B, Deleaval P, Jean G: Fluid overload correction and cardiac history influence brain natriuretic peptide evolution in incident haemodialysis patients. Nephrol Dial Transplant 2011;26:2630–2634.
18.
Fagugli RM, Palumbo B, Ricciardi D, Pasini P, Santirosi P, Vecchi L, Pasticci F, Palumbo R: Association between brain natriuretic peptide and extracellular water in haemodialysis patients. Nephron Clin Pract 2003;95:c60–c66.
19.
Booth J, Pinney J, Davenport A: N-terminal proBNP a marker of cardiac dysfunction, fluid overload, or malnutrition in hemodialysis patients? Clin J Am Soc Nephrol 2010;5:1036–1040.
20.
Davenport A, Willicombe MK: Does diabetes mellitus predispose to increased fluid overload in peritoneal dialysis patients? Nephron Clin Pract 2010;114:c60–c66.
21.
Wang TJ, Larsen MG, Benjamin EJ, Leip EP, Wilson PW, Vasan RS: Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594–600.
22.
Wahl HG, Graf S, Renz H, Fassbinder W: Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by haemodialysis. Clin Chem 2004;50:1071–1074.
23.
Fürstenberg A, Davenport A: Assessment of body composition in peritoneal dialysis patients using bioelectrical impedance and dual-energy x-ray absorptiometry. Am J Nephrol 2011;33:150–156.
24.
Papakrivopoulou E, Lillywhite S, Davenport A: Is N-terminal probrain-type natriuretic peptide a clinically useful biomarker of volume overload in peritoneal dialysis patients? Nephrol Dial Transplant 2012;27:396–401.
25.
Çelik G, Silinou E, Vo-Van C, Jean G, Chazot C: Plasma BNP, a useful marker of fluid overload in hospitalized haemodialysis patients. Hemodial Int 2012;16:47–52.
26.
Booth J, Pinney J, Davenport A: Do changes in relative blood volume monitoring correlate to hemodialysis-associated hypotension? Nephron Clin Pract 2011;117:c179–c183.
27.
Spalding EM, Chandna SM, Davenport A, Farrington K: Kt/V underestimates the haemodialysis dose in women and small men. Kidney Int 2008;74:348–355.
28.
Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, Haemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux on mortality and morbidity in maintenance haemodialysis patients: primary results of the HEMO study. N Engl J Med 2002;347:2010–2019.
29.
Booth J, Pinney J, Davenport A: The effect of vascular access modality on changes in fluid content in the arms as determined by multifrequency bioimpedance. Nephrol Dial Transplant 2011;26:227–231.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.